Anti-Hypertensive Drugs - Indonesia

Indonesia

The projected revenue of the Anti-Hypertensive Drugs market in Indonesia is expected to reach US$63.05m by 2024.
This revenue is projected to grow at an annual growth rate of 0.52% (CAGR 2024-2028), resulting in a market volume of US$64.36m by 2028.
In comparison to other countries globally, United States is expected to generate the highest revenue, reaching US$12,290.00m in 2024.
Indonesia's rising middle class and increasing healthcare awareness are driving the demand for anti-hypertensive drugs in the country.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Indonesia has been experiencing steady growth in recent years.

Customer preferences: Indonesian consumers are increasingly concerned about their health and are more willing to invest in preventative measures such as medication. Additionally, with a growing elderly population in Indonesia, there is an increasing demand for drugs that can help manage chronic conditions such as hypertension.

Trends in the market: There has been a trend towards the use of combination therapies in the treatment of hypertension in Indonesia. This involves the use of two or more drugs with different mechanisms of action to achieve better blood pressure control. Additionally, there has been an increasing focus on the development of generic drugs, which are more affordable for consumers and can help to increase access to treatment.

Local special circumstances: One of the challenges facing the Anti-Hypertensive Drugs market in Indonesia is the lack of access to healthcare in some areas of the country. This can make it difficult for patients to obtain the medication they need, particularly in rural areas. Additionally, there is a lack of awareness about hypertension and its treatment among some segments of the population, which can lead to underdiagnosis and undertreatment.

Underlying macroeconomic factors: The Indonesian economy has been growing steadily in recent years, which has led to an increase in disposable income for many consumers. This has helped to drive demand for healthcare products, including Anti-Hypertensive Drugs. Additionally, the Indonesian government has been investing in healthcare infrastructure and initiatives aimed at improving access to healthcare for all citizens. This is likely to continue to drive growth in the Anti-Hypertensive Drugs market in Indonesia in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.